Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
1 2 3 4 5 6 Next › Last »

FDA Rounds Out PFDD Guidance Series With Recommendations For COA-Based Endpoint Development, Specific Advice For Heterogeneous Conditions

April 6, 2023

PBM Transparency Featured At Senate Finance Committee Hearing; Wyden Looks Ready To Tackle “Big-League” Issue On “Bipartisan Basis”

April 6, 2023

Can FDA Save The Generic Industry? Chronic Shortages Are “Sign Of Strains” Facing Sector, CDER Director Warns; Statutory Update May Be Overdue

April 6, 2023

CDER Hiring “Doing Very Well,” Director Cavazzoni Says, Especially For Medical Officers: Still Needs For Stats And Inspectors; OTC Office Set To Rebound

April 6, 2023

Prevision Policy Clips | CMS Final Part D Rule Harmonizes “Gross” Drug Spending Definition

April 6, 2023

CBER Stepping Up Effort As Regulator/Stimulator Of Gene Therapy Commercial Efforts; Marks Says It Is Frustrating To See Late-Stage Projects Dropped

April 6, 2023

Prevision Policy Clips | CBER Director Marks Expects Pace Of Gene Therapy Approvals To Jump Substantially

April 5, 2023

Advisory Committee Tracker: Rexulti For Alzheimer’s Agitation, Long Awaited NASH Review Among Half Dozen New Topics Added By FDA

April 4, 2023

Prevision Policy Clips | Opioid “Mail-Back” Program Will Be Added To REMS

April 4, 2023

Prevision Policy Clips | CMS Updated List Of Part B Inflation Rebate Drugs No Longer Includes CAR-T Therapies

April 3, 2023

FDA Initiates PDUFA VII Digital Health Technologies Program: Workshop Highlights Early Progress, Framework Identifies Future Priorities

March 31, 2023

Prevision Policy Clips | Drug Pricing Legislation That Would Apply Inflation Rebates To Private Insurance Market, Move Baseline Year To 2016 Introduced

March 31, 2023

iPLEDGE 19-Day “Lockout” Period For Isotretinoin Patients Should Be Dropped, FDA Committee Says; Home Pregnancy Tests Should Continue

March 30, 2023

FDA Foreign Inspections Pilot Program Back On Track Post-COVID, Califf Tells House Budget Hearing; China Visits Will Commence In May

March 30, 2023

Prevision Policy Clips | FDA Establishes Lupus Clinical Trial Initiative

March 30, 2023

Prevision Policy Clips | Otsuka/Lundbeck Rexulti For Alzheimer’s Agitation Gets FDA Advisory Committee Review

March 29, 2023

Prevision Policy Clips | OTC Switch Of Contraception Drug Opill Advisory Committee Rescheduled And Expanded

March 28, 2023

Prevision Policy Clips | BrainStorm Says FDA To Convene Advisory Committee For RTFed NurOwn Cell Therapy For ALS

March 27, 2023

iPLEDGE REMS Review: FDA Floats End To Use Of At-Home Pregnancy Tests, But Wants Committee To Consider Loosening Other Isotretinoin Requirements

March 24, 2023

Oncology Accelerated Approval Policy Put In Writing: Randomization Is “Preferred,” FDA Says In Draft Guidance, But Plenty Of Exceptions

March 24, 2023

Drug Shortages Back In Congressional Spotlight: FDA “Essential Medicine” List May Need Rethinking, Quality Ratings Get A Boost From Testimony At Senate Hearing

March 24, 2023

Prevision Policy Clips | Accelerated Approval In Oncology: RCTs Preferred To Single-Arm Studies, FDA Confirms

March 24, 2023

HHS Intends To Conduct Part D Price Negotiations With Public Scrutiny, Secretary Becerra Tells Initial Capitol Hill HHS Budget Hearings

March 23, 2023

“March In” Debate Put On Back Burner, But Xtandi May Still Be Precedent In First Round Of Price Negotiation

March 23, 2023

Biogen/Ionis’ Tofersen For ALS Headed Toward Accelerated Approval; FDA Panel Confirms NfL As Surrogate Marker, But Not For “Full” Approval

March 23, 2023
1 2 3 4 5 6 Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Tweets by PrevisionPolicy

Copyright © 2023 Prevision Policy. All Rights Reserved. Privacy Policy